19.1 Catheter-Directed Thrombolysis (CDT) Protocols

Key Takeaways

  • Use territory, severity and bleeding risk to select candidates for catheter thrombolysis.

  • Match the catheter, treatment segment and line type to the labeled instructions and the ordered medication.

  • An ultrasound-assisted setup and a mechanical extraction device act differently. Verify indications and trial comparisons.

  • Trend clinical findings and prescribed laboratory tests, and escalate bleeding or neurologic change promptly.

Last updated: November 2026

19.1 Catheter-Directed Thrombolysis (CDT) Protocols

Clinical Core: Catheter-directed thrombolysis delivers a fibrinolytic drug through an infusion catheter positioned for a defined clot burden. Clinical urgency, bleeding risk, target territory and the intended endpoint determine whether it is appropriate.

Fibrinolysis and territory

Plasminogen activators such as alteplase help convert plasminogen to plasmin, which breaks down fibrin. Alteplase acts preferentially in the presence of fibrin. Local administration can use a different dose and delivery path from systemic administration, but systemic bleeding can still occur. The U.S. Activase label describes intravenous regimens for acute ischemic stroke, acute myocardial infarction and acute massive pulmonary embolism. These sections do not establish a catheter infusion order. Other thrombolytics have distinct approved indications, units and dosing. Never substitute a thrombolytic or use a systemic regimen as the catheter order.

SettingWhich distinction guides selection?
Acute lower-limb ischemiaFirst communicate limb viability and urgency. CDT is a revascularization option in selected salvageable cases. In a marginally threatened IIa limb it can be considered as an alternative to surgery. An immediately threatened IIb limb needs immediate restoration of perfusion, with a rapid catheter-based strategy considered in selected cases. Reperfusion is inappropriate for nonviable tissue.
Acute iliofemoral deep vein thrombosis (DVT)Anticoagulation remains foundational. SIR considers thrombus removal in selected patients with severe symptoms, extensive acute iliofemoral disease and low bleeding risk. ATTRACT did not establish a reduction in overall post-thrombotic syndrome incidence across its proximal DVT cohort and showed more early major bleeding with pharmacomechanical therapy.
Acute pulmonary embolism (PE)The 2026 U.S. multisociety guideline considers catheter-directed lysis plus anticoagulation reasonable in category E1, and allows consideration in D1–D2 when an advanced treatment is being considered. Use the physiologic findings in §13.2 and assess bleeding and other treatment options.

Two later 2026 randomized PE trials reported less early clinical deterioration on composite endpoints for selected intermediate-high-risk patients who received catheter-directed lysis and anticoagulation compared with anticoagulation alone. HI-PEITHO tested ultrasound-assisted treatment and PRAGUE-26 tested standard catheter-directed treatment. They enrolled different populations and did not compare the catheter methods head to head. SUNSET sPE, a separate head-to-head trial, did not show better thrombus reduction with ultrasound-assisted delivery than with standard infusion in its enrolled population. The choice of therapy depends on the clinical setting and team assessment.

Plan delivery and monitor

Review the bleeding history, recent procedures, intracranial disease, current anticoagulants and laboratory results with the team. Active internal bleeding ordinarily precludes lysis. Timing and contraindications depend on indication and drug. Confirm the intended solution, route, concentration and infusion rate with the ordered protocol, including the plan for anticoagulation and any separate coolant or sheath line. Do not use a universal sheath heparin regimen. In acute limb ischemia, for example, initial systemic anticoagulation while assessing revascularization and the question of therapeutic systemic heparin during catheter infusion are separate decisions.

Identify the clot segment, the treatment length and the radiopaque markers on the catheter. The U.S. Merit 4 Fr Fountain instructions mark the infusion zone with two bands and require its matched occluding wire to direct fluid through the side ports. They prohibit a power injector. EKOS+ combines infusion with a compatible ultrasound core and a separate coolant pathway. Boston Scientific prohibits a power injector connection to either luer. An ultrasound-assisted infusion is distinct from a clot-extraction device. Verify the product's indications, compatibility, settings and alarm response separately.

Worked check. Pharmacy supplies an ordered, deliberately hypothetical concentration of 0.20 mg/mL and the written order is 0.60 mg/h through a single specified catheter. The corresponding pump setting is 0.60/0.20=3.00.60/0.20=3.0 mL/h. If there are two catheters, verify whether the order specifies a rate per catheter or a total. This calculation does not establish any clinical dose.

During treatmentWhat should be communicated?
Catheter, pump or position concernThe exact line, labeled fluid, concentration, pump value, alarm and suspected displacement. Preserve the closed system and follow the designated safety response.
Bleeding or laboratory changeThe clinical findings, access site, medication and laboratory trend. Fibrinogen can be followed under specified protocols. Cohort findings vary, and no isolated universal cutoff determines the correct action for every territory.
New neurologic findings or hemodynamic deteriorationAn emergency for immediate escalation and activation of the applicable bleeding or stroke response. Follow the protocol for holding lysis and assessment, including urgent head imaging for suspected intracranial bleeding.
New severe limb pain or altered sensory or motor function after reperfusionEscalate urgently and consider recurrent ischemia, embolization or compartment syndrome. Follow the actual clinical examination and directed evaluation.

Repeat imaging or clinical assessment verifies flow and residual clot according to the protocol. Report any underlying stenosis, new embolus or unexpected outflow finding so that the operator can determine whether adjunctive treatment is needed.

Loading diagram...
Catheter Thrombolysis Planning and Surveillance
Test Your Knowledge

A patient has acute lower-limb ischemia with a new motor deficit and an immediately threatened, salvageable limb. Which concern should drive procedural preparation?

A

The limb can be rechecked after a routine overnight infusion.

B

A motor deficit makes reperfusion inappropriate in every case.

C

The team must restore flow immediately and select a strategy fast enough for the limb.

D

The peripheral pulse alone can establish the duration of the clot.

Test Your Knowledge

An order for a single infusion catheter specifies 0.60 mg/h. The verified solution is 0.20 mg/mL. What pump rate corresponds to that order?

A

0.12 mL/h

B

0.33 mL/h

C

1.2 mL/h

D

3.0 mL/h

Test Your Knowledge

During catheter thrombolysis, a patient develops sudden new speech difficulty. Which response is appropriate?

A

Activate emergency evaluation and follow the protocol for suspected intracranial bleeding or stroke.

B

Wait for the next planned fibrinogen result before escalating.

C

Increase the catheter infusion in case the new symptom resolves.

D

Finish the scheduled infusion before obtaining a neurologic assessment.

Sections you finish are checked off in the contents.